Fate Therapeutics, Inc.
(NASDAQ : FATE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.00%75.320.0%$2388.00m
NVAXNovavax, Inc. 9.37%171.8999.2%$1276.26m
GILDGilead Sciences, Inc. -2.42%69.171.0%$527.06m
AMGNAmgen, Inc. -0.97%241.241.3%$510.65m
REGNRegeneron Pharmaceuticals, Inc. -2.40%632.862.5%$464.17m
SRNESorrento Therapeutics, Inc. 4.83%13.461.8%$437.39m
BNTXBioNTech SE -2.37%81.200.0%$403.10m
VRTXVertex Pharmaceuticals, Inc. -1.34%272.031.9%$379.44m
VXRTVaxart, Inc. 10.51%9.830.0%$330.86m
ILMNIllumina, Inc. 2.31%402.793.5%$327.35m
BIIBBiogen, Inc. -0.01%276.071.6%$326.91m
IBIOiBio, Inc. 0.68%4.421.8%$183.89m
EBSEmergent BioSolutions, Inc. 8.27%132.776.4%$175.20m
SGENSeattle Genetics, Inc. -1.11%163.246.1%$173.17m
ALXNAlexion Pharmaceuticals, Inc. -2.44%102.662.0%$170.71m

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.